Filed Electronically

February 13, 2023

Chiquita Brooks-LaSure
CMS Administrator
200 Independence Avenue, SW
Washington DC

Re: Medicare Program; Contract Year 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, Medicare Parts A, B, C, and D Overpayment Provisions of the Affordable Care Act and Programs of All-Inclusive Care for the Elderly; Health Information Technology Standards and Implementation Specifications (“2024 MA Proposed Rule” or “Proposed Rule”)

Dear Administrator Chiquita Brooks-LaSure:

The undersigned members of the Regulatory Relief Coalition (RRC), representing thousands of physicians throughout the United States, write to thank you for the comprehensive prior authorization (PA) requirements in the contract year (CY) 2024 MA and Part D Proposed Rule. The RRC is a group of national physician specialty organizations advocating for regulatory burden reduction to ensure that utilization review policies are not a barrier to timely and equitable access to care for the patients we serve.

The RRC strongly supports the regulatory changes set forth in the Proposed Rule. We applaud CMS for its thorough and comprehensive proposed regulations, which, when finalized, will limit MA plans’ overuse and abuse of PA, reduce barriers to care and lessen provider burden. Finalizing the provisions in this Proposed Rule will help ensure that Medicare beneficiaries who enroll in MA Plans have the same access to Medicare-covered items and services as beneficiaries who opt for Medicare Fee-for-Service (FFS). Additionally, the issuance of this Proposed Rule in conjunction with the electronic PA (e-PA) proposed rule (which includes MA plans)1 will improve the efficiency of PA processes, reduce delays in care and alleviate the burden associated with PA.

The comments and suggestions set forth below should be viewed as our attempt to help to further improve an already praiseworthy proposal, identify potential gaps in the Proposed Rule’s patient

---

1 Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children’s Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-Facilitated Exchanges, etc. [CMS–0057–P] RIN 0938–AU87. 87 Federal Register 238 at 76238 (December 13, 2022).
protector's and point to possible future directions.

I. Consistency of Regulatory and Potential Legislative PA Requirements

Over the past several years, members of Congress have become increasingly concerned about the barriers to patient access resulting from MA plans’ use of PA. To address many of the same deficiencies in MA plans’ use of PA as those identified by CMS in the 2024 MA and e-PA Proposed Rules, the House of Representatives unanimously passed the Improving Seniors’ Timely Access to Care Act (S. 3018/H.R. 3173) (the “Improving Seniors’ Access bill” or “the Bill”) by voice vote in September 2022. This bipartisan legislation, developed with input from the RRC, finished the 117th Congress with 380 combined co-sponsors — 53 senators and 327 representatives — supporting the legislation. Importantly, more than 500 organizations representing patients, health care providers, the medical technology and biopharmaceutical industry, health plans, and others endorsed the legislation.

We note that the purposes of the PA provisions of the MA and e-PA Proposed Rules and the Bill closely align. Both the Proposed Rules and legislation acknowledge that PA:

- Plays an important role in utilization management, but it can be misused or overused, creating considerable challenges for patients, providers, and payers;
- Presents a serious health risk for patients when care is delayed;
- Increases provider and payer burden due to inconsistent payer policies, provider workflow challenges, and unpredictable use of electronic standards; and
- Contributes to significant provider burnout.

We also note that the Bill and the approach to PA taken by CMS in the MA and the e-PA Proposed Rules include many similar elements. The e-PA Proposed Rule and the legislation both:

- Require MA plans to adopt e-PA;
- Ensure that MA plans respond to PA requests within specific timeframes;
- Require public reporting on the use of PA;
- Support waiver or modification of PA requirements based on provider performance; and
- Recognize that health plans’ proprietary interfaces and web portals through which providers submit their requests remain inefficient and burdensome.

We recognize that several areas of divergence between the CMS regulatory approach and the approach reflected in the bill relate to PA issues addressed in the e-PA Proposed Rule rather than in the 2024 MA Proposed Rule. However, to expedite adoption, we strongly urge CMS to include in the 2024 MA Final Rule provisions that address several concerns addressed by both the Bill and the e-PA Proposed Rule. Specifically, the RRC urges CMS to adopt in the 2024 MA Plan Final Rule regulations and policy changes that mirror provisions in the Improving Seniors’ Access bill and that can be implemented by MA Plans in their 2024 Contract Year.

- **Recommendation One: Deadlines for PA Decisions.** The RRC urges CMS to require MA Plans to respond to PA requests within the timelines set forth in the Improving Seniors’ Access bill. While the Proposed Rule does not explicitly address PA deadlines, this issue is addressed — for MA plans and other health plans — in the e-PA Proposed Rule. While both
the Bill and the e-PA Proposed Rule allow 7 days for a standard determination, the Bill requires MA plans to respond to an urgent PA request within 24 hours and the e-PA Proposed Rule establishes a longer deadline. To ensure that MA enrollees receive timely care in emergent situations and to ensure consistency between regulatory and potential legislative requirements, the RRC supports the 24-hour deadline for PA decisions in urgent situations. We also believe that MA plans have the technological capability to implement these deadlines in 2024, and that the MA Final Rule should require them to do so.

- **Recommendation Two: Transparency.** Both the Bill and the e-PA Proposed Rule would require MA plans to make available to the public certain data regarding their PA decisions, including, for example, the proportion of PA requests approved and denied, both initially and on appeal. The Bill and the e-PA Proposed Rule differ with respect to the data elements that must be disclosed, whether the data must be disclosed on an individual service basis and the manner of disclosure. For example, the Bill requires plans to disclose this information to CMS for public display and the e-PA Proposed Rule requires MA plans to self-disclose on their websites.

The RRC believes that it is critical that PA data be disclosed on an individual service basis, as disclosure on an aggregate basis will likely be virtually meaningless to both providers and patients. Further, in order to facilitate access to this data during the open enrollment period, this data should be accessible, along with other MA plan data, on CMS’ website. Health plans have the capability to provide this data (and, in fact, already do so on an individual service basis). We do not believe that transparency of PA decision making should be delayed until enactment of the Bill or until January 1, 2026, as proposed in the e-PA Proposed Rule. For this reason, we request that CMS include in the 2024 MA Final Rule transparency requirements that fully parallel those in the Bill.

- **Recommendation Three: E-Prior Authorization.** While the Bill would require MA plans to institute a real-time electronic prior authorization program for items and services that are frequently approved, the e-PA Proposed Rule does not include this requirement. We recognize that MA plans may not be able to institute such a program in their 2024 Contract Year, and the Bill itself would not require implementation until three years after enactment. However, we urge CMS to include in the 2024 MA Final Rule a provision that requires MA Plan 2024 Contract bids to include a plan for the implementation of real time decision making and a proposed timeframe.

II. Application of PA Requirements to Step Therapy and Drugs Covered under Part D

Together, payers, manufacturers, physicians and patients incur approximately $93.3 billion in costs annually to implement, contest and navigate utilization management.\(^2\) We recognize that the statutory

\(^2\) Payers spend approximately $6.0 billion annually administering drug utilization management, and manufacturers spend approximately $24.8 billion supporting patient access in response. Physicians devote approximately $26.7 billion in time spent navigating utilization management, whereas patients spend approximately $35.8 billion annually in drug cost sharing, even after taking advantage of manufacturer and philanthropic sources of financial support. [https://www.healthaffairs.org/author/Howell%2C+Scott](https://www.healthaffairs.org/author/Howell%2C+Scott)
and regulatory requirements applicable to PA under Medicare Part D differ from, and in many respects are more comprehensive than, the PA requirements that historically have been applicable to other items and services provided by MA plans to enrolled beneficiaries. For example, PA restrictions imposed by Part D plans and MA plans offering Part D coverage require CMS approval, e-PA requirements already have been adopted for Part D prescription drugs, and an e-PA program is already required for Part D drugs.

Nonetheless, recent research suggests that there are significant disparities in access to drugs for minority populations covered by Medicare. In addition, a recent study indicates substantial variation in step therapy protocols, and many step therapy restrictions are not supported by published clinical literature or practice guidelines. Specifically, using data from seventeen of the largest US commercial health plans, the authors examined step therapy protocols that determined patients’ eligibility for specialty drugs and identified ten diseases that are often subject to that requirement. Overall, plans applied step therapy in 38.9 percent of drug coverage policies, with varying frequency across plans (20.6–57.5 percent). Of the protocols for the ten diseases, 34.0 percent were consistent with corresponding clinical guidelines, 55.6 percent were more stringent, and 6.1 percent were less stringent. Trials of alternatives not included in the clinical guidelines were required in 4.2 percent of protocols, and the consistency of protocols varied within and across plans. The authors concluded that these findings raise questions about potentially overly restrictive step therapy protocols, as well as concerns that variability across health plans makes protocols onerous for patients and practitioners alike. Under these circumstances.

- **Recommendation Four: Part D Drug Step Therapy.** We do not believe that step therapy requirements are ever appropriate in situations where the patient has a terminal illness, such as cancer. We also request that CMS extend the transparency and other coverage requirements described in the Proposed Rule to Part D step therapy, formulary limitations, and other Part D drug coverage restrictions imposed by Part D sponsors, including MA plans. In particular, we believe that sponsors of Part D drug plans should be required to base PA criteria for drugs (as well as for other items and services provided to Medicare enrollees) on treatment guidelines or clinical literature that is made publicly available to CMS, enrollees and providers, and that Part D plan sponsors should be required to post a public summary of evidence that was considered in establishing PA drug criteria. Part D coverage should not be limited based on internal, proprietary, or external clinical criteria that are not disclosed both to the public and to the Medicare Program.

Furthermore, we are concerned that CMS asserts in this proposed rule that, “The requirements in the 2019 rule, in combination with current MA program regulations, ensure access to Part B drugs and limit the potential for step therapy policies to interfere with medically necessary care.” We respectfully

---


disagree that the current allowances made for MA plan step therapy Part B drug protocols meet this standard, instead creating unnecessary burdens and irreparable consequences when it comes to the health and wellness of patients.

Numerous cases of patient harm due to the utilization of step therapy protocols have been documented and the beneficiaries receiving Part B covered drugs include some of the most vulnerable in the program. As enrollment in MA plans rapidly grows, including Special Needs Plans, addressing this barrier to care becomes increasingly urgent. The 2024 MA Final Rule presents an opportunity to reconsider the agency’s position on step therapy of Part B drugs and ensure equitable access to care for MA beneficiaries.

- **Recommendation Five: Part B Drug Step Therapy.** We urge the Administration to protect patients’ access to care and expeditiously reverse the harmful decision to allow MA plans to implement step therapy of Part B drugs through the 2024 MA Plan Final Rule. If that is not possible, we urge the Agency to reconsider the policy through e-PA rulemaking.

III. **Continuity of Care**

The Proposed Rule provides that MA plans must provide a minimum 90-day transition period when an enrollee switches plans. In addition, the MA Proposed Rule solicits comments on whether PA should be required to be valid for the duration of the prescribed order or ordered course of treatment.

The RRC strongly believes that approval should be valid for the duration of the prescribed order or ordered course of treatment. In this regard, we note that the payer-to-payer application programming interfaces that would be required under the e-PA Proposed Rule would facilitate implementation of this policy.

- **Recommendation Six: Continuity of Care.** The RRC recommends that when a Medicare beneficiary switches MA Plans, the predecessor plan’s approval of a course of therapy should be valid for the duration of the prescribed order or ordered course of treatment.

IV. **MA Plans’ Use of Internal Coverage Criteria in addition to Requirements in Current Regulations.**

MA plans require PA to ensure that items or services to be provided to enrollees are medically necessary. The Medicare Program Integrity Manual (at Section 13.5.4) defines the criteria to be used by Medicare Administrative Contractors (MACs) in determining whether an item or service is medically necessary.

---


necessary for the purposes of Local Coverage Determinations. In making this determination, a MAC is
required to consider whether the item or service is:

- Safe and effective;
- Not experimental or investigational (exception: routine costs of qualifying clinical trial services
  with dates of service on or after September 19, 2000, which meet the requirements of the
  Clinical Trials National Coverage Determination (NCD) are considered reasonable and
  necessary); and
- Appropriate, including the duration and frequency that is considered appropriate for the item or
  service, in terms of whether it is:
  - Furnished in accordance with accepted standards of medical practice for the diagnosis or
    treatment of the patient’s condition or to improve the function of a malformed body
    member;
  - Furnished in a setting appropriate to the patient’s medical needs and condition;
  - Ordered and furnished by qualified personnel;
  - One that meets, but does not exceed, the patient’s medical need; and
  - At least as beneficial as an existing and available medically appropriate alternative.

We believe that the criteria used by MA plans in establishing coverage criteria for items and services for
which there is no applicable NCD or Local Coverage Determination (LCD) should be limited to the three
criteria that may be considered by a MAC in making an LCD and that MA plans should not be authorized
to apply criteria other than those set forth above. To allow MA plans to utilize internal coverage criteria
other than those used by MACs under the applicable Manual is inconsistent with the governing statute.

- **Recommendation Seven: No internal coverage criteria.** The RRC recommends that CMS
  limit the medical necessity criteria that may be used by MA plans to the criteria set forth in
  the Medicare Integrity Manual Section 13.5.4., as cited above.

V. **Opportunity for Public Comment on MA Plan Coverage Determinations**

The RRC strongly supports those provisions of the Proposed Rule that require MA plans to post public
summaries of the evidence used in determining coverage and that preclude MA plans from relying on
internal data or other sources not available to the public. We believe that requiring transparency with
respect to the establishment of MA plans’ coverage determinations has the potential to dissuade MA
plans from establishing coverage restrictions that are clearly unsupported by any clinical evidence.
However, we believe that making these summaries subject to public comment would enable MA plans
to consider the views of experts in the field and would help ensure that coverage determinations are
balanced.

- **Recommendation Eight: Public Comment on Coverage Criteria.** We recommend that MA
  plans’ coverage determinations and supporting documentation summaries be subject to
  public comment utilizing the same procedural safeguards applicable to MACs’ LCDs.

- **Recommendation Nine: Inclusion of any Applicable PA Requirements in MA Plan Coverage
  Policies.** The Proposed Rule requires that an MA plan’s coverage policy with respect to an
  item or service not subject to an NCD or LCD must be made public, along with supporting
VI. **Utilization Management (UM) Committee**

In the Proposed Rule, CMS solicits comments on whether an MA plan’s UM committee should be charged with ensuring that the UM policies and procedures are developed in consultation with contracted providers; whether the UM committee should ensure, as required by § 422.202(b)(2), that MA organization communicates information about practice guidelines and UM policies to providers and, when appropriate, to enrollees; and whether the UM committee should have an ongoing or active oversight role in ensuring that decisions made by an MA plan throughout the year are consistent with the final, approved practice guidelines and UM policies.

- **Recommendation Ten: UM Composition.** We strongly believe that physicians participating in an MA plan’s network should be well represented on the plan’s UM Committee. In fact, the governing statute requires such participation.

- **Recommendation Eleven: UM Composition – Specialist Representation.** We appreciate CMS soliciting feedback on recommendations for other types of providers that should also be included on the UM committee. To ensure coverage policies reflect current practice patterns and the real-world experiences of clinicians and their patients, we believe it is critical that the plan’s UM committee include at least one clinician, who is free from conflicts of interest, not employed by the plan, and who has current expertise in the use or medical need for that specific item or service.

- **Recommendation Twelve: Revision of UM Policies.** The Proposed Rule requires an MA plan to revise UM policies and procedures as necessary, at least annually. Please note, however, that the governing statute requires that an MA plan discloses to potential enrollees the services subject to PA “at the time of enrollment.” Allowing MA plans to add PA requirements to additional services during the plan year would undermine the intent of this statutory provision. For this reason, we urge CMS to clarify that only new services not available at the time of enrollment can be added to the list of services that require PA.

- **Recommendation Thirteen: Pre-Existing MA Plan Coverage Policies.** The Proposed Rule indicates that an MA plan’s UM committee must ensure that all coverage policies are approved prior to 2024. However, the Proposed Rule does not appear to specifically address the question of whether coverage policies that are currently in effect can be approved by the UM Committee if the coverage policy (along with clinical support) has not been publicly disclosed, as required elsewhere in the Proposed Rule. We recommend that the 2024 MA final rule clarify that MA coverage policies must be publicly disclosed, along with the supporting clinical literature, before the MA plan submits its 2024 bid. In addition, 2024 MA plan bids should include a certification signed by the plan’s medical director (the UM committee chair) that all the MA plan’s coverage policies, including clinical support for medical documentation. However, it does not appear to require that the coverage document disclose whether PA is required. We recommend that coverage policies issued by an MA Plan be required to include disclosure of any applicable PA requirements, the effective date of any such requirements, and a list of the specific medical documentation that will be required for PA approval.
VII.  Peer-to-Peer Determinations

The Proposed Rule would require that physician or other appropriate health care professional who reviews a PA decision must “have expertise” in the relevant field of medicine before a PA request is denied. In this regard, the Proposed Rule requires the reviewing physician for a PA determination to have the same level of qualifications currently required for peer-to-peer reconsideration requests. However, for both PA decisions and reconsideration determinations, the Proposed Rule explicitly does not require the reviewing physician to be in the same specialty as the performing physician.

While we understand the scarcity of physicians available to conduct PA and reconsideration determinations, we are concerned that physicians utilized by MA plans to engage in peer-to-peer interactions are all too often unfamiliar with the services involved, and treating physicians spend altogether too much time providing health plan clinicians (who are not always even physicians) with basic clinical background.

- **Recommendation Fourteen: Specialty Qualifications of Reviewing Physicians.** The RRC recommends that CMS modify the Proposed Rule to require that reviewing physicians be in the same specialty as the treating physician for both all initial medical necessity determinations (including PA decisions) and reconsideration determinations.

- **Recommendation Fifteen: Scheduling Peer-to-Peer Consultations.** We also note that peer-to-peer consultations are typically scheduled at the convenience of the reviewing physician, resulting in significant inconvenience for treating physicians and their patients. We urge CMS to encourage MA plans to utilize modern telecommunications technologies to schedule and conduct peer-to-peer meetings and that these scheduled conversations occur when it is mutually convenient for the treating physician and the plan representative.

VIII.  Payment for Approved Services

All too often, a physician obtains PA for a service only to find that the MA plan ultimately denies payment. The RRC firmly believes that if an MA plan provides PA for a service, the physician should be paid — no further questions asked. Any question related to the medical necessity of the service should be considered resolved once prior approval is obtained.

- **Recommendation Sixteen: Payment for Approved Services.** The RRC requests that CMS modify the applicable regulations to specifically state that the approval of a PA requests constitutes and “organization determination” which is considered final.

Issues also frequently arise when a physician obtains prior approval for a surgical or other procedure/service only to find during the surgery or procedure/service that, due to the patient’s particular anatomy or other unforeseen circumstances, an additional medically related procedure(s) is required. In these cases, MA plans often deny these additional, medically necessary procedures or services. For example, a gastroenterologist may discover a polyp in a patient undergoing a routine colonoscopy that needs removal. It is unreasonable for the physician to contact the health plan while...
the patient is anesthetized to gain additional authorization. It is also inefficient, unreasonable, and ultimately more expensive for the patient to schedule another appointment to remove the polyp.

- **Recommendation Seventeen: Incidental Surgical or other Procedures/Services.** The RRC requests that CMS make it clear that surgical or other procedures/services performed incident to a procedure that has received prior approval and that are medically related and necessary to furnish the approved procedure may not be denied for failure to obtain prior approval. The MA plan may subsequently choose to challenge the medical necessity of such incidental procedures but cannot peremptorily deny them for failure to obtain prior approval. In addition, the MA plan must cover and pay for the authorized services.

**IX. Enforcement and Oversight**

We very much appreciate the comprehensive, in-depth approach reflected in the Proposed Rule concerning the MA plans’ establishment of coverage criteria and PA requirements. We believe that it may also be important for CMS to address in the final rule or in subregulatory guidance an explanation of how the agency intends to ensure that the MA plans implement the new requirements in a timely manner. For example, it is unclear what recourse will be available to patients and providers if an MA plan establishes a coverage policy that is more restrictive than the policy set forth in a NCD or applicable LCD, thereby effectively denying MA enrollees access to services that are covered for Medicare FFS beneficiaries in the same area.

- **Recommendation Eighteen: Oversight and Enforcement.** The RRC urges CMS to establish a plan for overseeing the implementation of the new requirements and to describe that plan in the preamble to the 2024 MA final rule. In this regard, we urge CMS to consider establishing a patient portal for patient and provider complaints about MA plan coverage policies and PA processes.

**X. Need for Limit on Number of Procedures Subject to PA**

We ask CMS to consider adopting policies that reduce the overall volume of PA requirements MA plans can impose on certain benefit categories, like basic Medicare benefits. We also ask CMS to address the increased use of peer-to-peer consultations and put in place guardrails to reduce the volume of these requirements. PA requirements inherently delay care — particularly since so few PA decisions are provided in real-time — and the only way to truly address care delays is to reduce the overall volume of PA requirements. A cornerstone of the *Improving Seniors’ Access* bill is its provisions requiring CMS to establish a real-time decision-making process for routinely approved services. Such an approach would significantly reduce PA burden and care delays. Additionally, such standards would ensure that PA requirements are only imposed when there is a genuine risk of overutilization of an item or service that Medicare FFS would otherwise cover.

- **Recommendation Nineteen: Real-Time PA Decisions.** The RRC urges CMS to establish standards for real-time e-PA for routinely approved services consistent with the process outlined in the *Improving Seniors’ Access* bill.

- **Recommendation Twenty: Exempting Physicians from PA.** We encourage CMS to require
MA plans to implement processes that allow high-performing physicians to bypass PA altogether. For example, the GOLD CARD Act of 2022 (H.R. 7995) would exempt providers who received approval for 90% of their requests in the last 12 months from PA.

XI. Conclusion

The RRC appreciates the opportunity to comment on the Proposed Rule and looks forward to working closely with CMS to further refine regulatory requirements to ensure that all Medicare beneficiaries — whether enrolled in MA or covered under Medicare FFS — obtain equal access to covered benefits. If you have any questions or need additional information, do not hesitate to contact us.

Sincerely,

American Academy of Family Physicians
American Academy of Neurology
American Academy of Ophthalmology
American Academy of Physical Medicine and Rehabilitation
American Association of Neurological Surgeons
American Association of Orthopaedic Surgeons
American College of Cardiology
American College of Rheumatology
American College of Surgeons
American Gastroenterological Association
American Medical Rehabilitation Providers Association
American Osteopathic Association
Association for Clinical Oncology
Congress of Neurological Surgeons
Medical Group Management Association
North American Spine Society
Society for Cardiovascular Angiography and Interventions
The National Association for Proton Therapy